NEW YORK--(BUSINESS WIRE)--
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation (XON) resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.
On April 21, 2016, Spotlight Research published a report on Intrexon asserting, among other things, that: (1) Intrexon’s technology has recently been questioned by high-ranking officials from the WHO, CDC and NIH; (2) Intrexon overstated revenues by 50% through transactions with related parties; (3) Intrexon’s technology platform is an overhyped, undifferentiated collection of commodity and failed products; and (4) Intrexon is the Theranos of the public markets. On this news, shares of Intrexon fell $9.73 per share or over 26% to close at $27.10 per share on April 21, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Intrexon investors. If you purchased shares of Intrexon on or before April 20, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-882.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.